Serum calprotectin (S100A8/A9) levels as a new potential biomarker of treatment response in Hodgkin lymphoma

ŞUMNU Ş., MEHTAP Ö., MERSİN S., TOPTAŞ T., DAĞLIÖZ GÖRÜR G., GEDÜK A., ...More

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, vol.43, pp.638-644, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 43
  • Publication Date: 2021
  • Doi Number: 10.1111/ijlh.13559
  • Journal Name: INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE
  • Page Numbers: pp.638-644
  • Keywords: biomarker, calprotectin, Hodgkin lymphoma, A9, SUPPRESSOR-CELLS, EXPRESSION, DIFFERENTIATION, CARCINOMA, GROWTH, TARC
  • Kocaeli University Affiliated: Yes

Abstract

Introduction Hodgkin lymphoma (HL) is unusual among malignancies, with inflammation playing such a prominent role in its pathogenesis. S100A8/A9 (calprotectin) is a heterodimeric protein, which has a role in the inflammatory response and oncogenesis. In this study in HL patients, the correlation between serum S100A8/A9 levels and treatment responses was investigated along with whether this marker is correlated with other inflammatory markers.